Kevin Kropf - Laboratory Specialist - Boehringer Ingelheim
WEBLaboratory Specialist. Boehringer Ingelheim. View Kevin Kropf’s profile on LinkedIn, the world’s largest professional community. Kevin has 1 job listed on their profile. See the complete...
- Title: Laboratory Specialist at …
- Location: Boehringer Ingelheim
- Connections: 3
1300P Treatment sequences in BRAF-V600-mutant non-small cell …
WEBTargeted treatment with BRAF/MEK-inhibitors of patients with metastatic BRAF-V600-mutated (BRAFm) non-small-cell lung cancer (NSCLC) is effective but limited by acquired resistance. Patients with BRAFm NSCLC may derive long-lasting benefit from immune checkpoint inhibition with PD-1/-L1 antibodies (CPI). While CPI are the preferred first-line (1L) therapy in BRAFm melanoma, the optimal ...
1334P PET/CT-guided immune checkpoint blocker treatment …
WEBOptimal duration of immune checkpoint blocker (ICB)-treatment in lung cancer has not been determined yet. One in five patients treated with first-line ICB achieves durable responses for ≥2 years. Treatment continuation beyond 2 years impacts on economic burden and might cause avoidable toxicities. Thus, safe discontinuation strategies …
BI & Enara Bio Enter Strategic Collaboration | BI US - Boehringer Ingelheim
WEBThis new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara …
20+ "Kevin Kropf" profiles | LinkedIn
WEBView the profiles of professionals named "Kevin Kropf" on LinkedIn. There are 20+ professionals named "Kevin Kropf", who use LinkedIn to exchange information, ideas, and...
Accelerating new cancer medicines in partnership ... - Boehringer Ingelheim
WEBFeb 8, 2024 · The partnership with CBmed will enable Boehringer Ingelheim to identify and validate biomarkers for projects across its growing cancer pipeline to support early proof of therapeutic effect, identification of new indications and patient selection.
WEBInterests, Personal, Invited Speaker: Roche, Incyte, Servier; Financial Interests, Institutional, Research Grant: Bayer, Chugai, BMS, Incyte, MSD. M. Sebastian ...
Life forward | Boehringer Ingelheim
WEBIt's the essence of who we are and how we want to be perceived: as leaders in human medicine and animal health, as partners and supporters, as problem solvers and forward thinkers. Life forward expresses what we want to achieve and how we behave. We are life forward, and we take life forward.
WEBJan 5, 2024 · Under the terms of the agreement, Boehringer Ingelheim will receive exclusive, worldwide rights from Kyowa Kirin to develop novel, first-in-class treatments for fibro-inflammatory diseases.
Kevin D Kropf - Facebook
WEBKevin D Kropf | Facebook. About. Worked at Boehringer Ingelheim Vetmedica. College. Studied at Northwest Missouri State University. High school. Went to Maryville High. Photos. See all photos. Others Named Kevin D Kropf. See more. Others With a Similar Name. Kevin D Kropf is on Facebook.
Skip to content